Multiple Myeloma

The AJMC^® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

Health disparities word cloud | Image Credit: Colored Lights-stock.adobe.com

Delays in Myeloma Oral Therapy Linked to Race, Age

By Maggie L. Shaw

October 11th 2024

Outcomes of interest in this study were time from diagnosis to initial prescription fill for an oral multiple myeloma (MM) medication and time from initial diagnosis to receipt of any treatment for MM.

Surbhi Sidana, MD, MBBS, Stanford University

Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care

By Maggie L. Shaw

October 2nd 2024

Multiple myeloma | Image credit: freshidea - stock.adobe.com

Varied Types, Levels of Support Needed for Patients With Multiple Myeloma

By Julia Bonavitacola

September 20th 2024

Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center

Bridging Global Treatment Gaps in Relapsed Multiple Myeloma

By Maggie L. Shaw

September 17th 2024

Clinical trial results | Image Credit: Egor-stock.adobe.com

D-VRd Boosts MRD Negativity in Transplant-Eligible Multiple Myeloma

September 12th 2024

EHA 2024: Highlights in Multiple Myeloma

Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024.

Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024.

Continuing Medical Education

October 13th 2024

Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care

1.0 Credits / Hematologic Cancer, Oncology

October 13th 2024

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

October 13th 2024

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer

More News

scientists in lab

December 22nd 2021

Phase 1/2 Trial Results Underscore Teclistamab’s Efficacy in RRMM

Updated results of the MajesTEC -1 phase 1/2 study on teclistamab showed the treatment resulted in an overall response rate of 62% among heavily pretreated patients with multiple myeloma.

Robert Rifkin, MD, FACP

December 20th 2021

Dr Robert Rifkin Explains the Importance of Real-world Data in MM Patient Populations

Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, describes his research on real-world treatment patterns among patients with triple-class refractory multiple myeloma.

iStopMM: Investigators From Iceland Report First Results of Population-Based Screening for Multiple Myeloma

December 18th 2021

iStopMM: Investigators From Iceland Report First Results of Population-Based Screening for Multiple Myeloma

Five years ago, investigators in Iceland sought to evaluate what would happen if screening for MGUS were widely available—and whether it would improve overall survival.

Picture of abnormal cells in bone marrow

December 15th 2021

Sub-Q Isatuximab Combo Offers Safety, Efficacy Profile Comparable With Phase 3 Results in IV Formulation

Subcutaneous (sub-Q) administration of isatuximab plus pomalidomide may provide survival advantages for patients with relapsed and refractory multiple myeloma, making it another treatment option for this patient group.

December 8th 2021

The MMRF: Understanding and Sharing the Genomic Landscape of Multiple Myeloma

The Effect of Evolving Treatment Options on the Management of Multiple Myeloma

December 8th 2021

The Effect of Evolving Treatment Options on the Management of Multiple Myeloma

blue cross

December 6th 2021

Postmarketing Surveillance Study Finds Ixazomib Safety Profile Acceptable in RRMM

Real-world evidence from Japan found ixazomib has an acceptable safety profile in patients with relapsed/refractory multiple myeloma (RRMS).

pills in box

December 1st 2021

Real-world Evidence Details Use of Ixazomib as Maintenance Therapy for MM

Results of a retrospective study conducted in China assessed the safety and efficacy of ixazomib for multiple myeloma.

elderly woman

April 4th 2021

Older Patients With MM Can Forgo Steroids in Treatment and See Similar Outcomes

Laura Joszt, MA

The combination of lenalidomide with steroid dexamethasone is standard of care in multiple myeloma (MM), but new research shows older patients can be spared the steroids.

red blood cells

March 25th 2021

Trial Analyzes Efficacy of Tailoring MM Treatment to MRD Response

Twice weekly high doses of carfilzomib in combination with lenalidomide and dexamethasone was tolerable and effective among patients with newly diagnosed multiple myeloma.

Optimizing the Use of MRD Testing in Multiple Myeloma

March 18th 2021

Optimizing the Use of MRD Testing in Multiple Myeloma

Laura Joszt, MA

Minimal residual disease (MRD) is being used more frequently in clinical trials and to identify the best treatment course for patients, but unknowns remain about the optimal use of MRD testing.

Highlighting Resiliency During Multiple Myeloma Awareness Month 2021

March 13th 2021

Highlighting Resiliency During Multiple Myeloma Awareness Month 2021

Multiple myeloma is not easily diagnosed, and its early symptoms may be confused for another condition.

CAR T Therapy Induces Response in Majority of Patients With Relapsed Multiple Myeloma

March 10th 2021

CAR T Therapy Induces Response in Majority of Patients With Relapsed Multiple Myeloma

Laura Joszt, MA

Idecabtagene vicleucel induced progression-free survival up to 20 months and a complete response in one-third of patients with multiple myeloma who had relapsed multiple times and had received at least 3 previous lines of treatment.

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions